Effect of time and titer in convalescent plasma therapy for COVID-19
Summary: The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment...
Main Authors: | Paola de Candia, Francesco Prattichizzo, Silvia Garavelli, Rosalba La Grotta, Annunziata De Rosa, Agostina Pontarelli, Roberto Parrella, Antonio Ceriello, Giuseppe Matarese |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S258900422100866X |
Similar Items
-
Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients
by: Connor J. Dwyer, et al.
Published: (2021-06-01) -
The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
by: Shinta Oktya Wardhani, et al.
Published: (2021-07-01) -
Classification of HIV virological failure using whole blood versus plasma viral load
by: Khan, Aabida
Published: (2017) -
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
by: Michele L. Donato, et al.
Published: (2021-03-01) -
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
by: Abhinay Gontu, et al.
Published: (2021-02-01)